Strs Ohio Increases Stake in IQVIA Holdings Inc. $IQV

Strs Ohio grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 151,039 shares of the medical research company’s stock after acquiring an additional 3,851 shares during the period. Strs Ohio’s holdings in IQVIA were worth $28,688,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Asset Dedication LLC lifted its position in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH bought a new position in shares of IQVIA in the second quarter worth about $39,000. J.Safra Asset Management Corp lifted its position in shares of IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares in the last quarter. Rothschild Investment LLC grew its stake in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the period. Finally, Root Financial Partners LLC purchased a new stake in IQVIA in the 3rd quarter worth approximately $43,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IQV. Mizuho set a $266.00 price target on shares of IQVIA in a research report on Friday, January 9th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Stifel Nicolaus raised their price target on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Stock Down 1.6%

IQV opened at $235.20 on Friday. The company has a market capitalization of $40.05 billion, a PE ratio of 32.26, a price-to-earnings-growth ratio of 2.43 and a beta of 1.36. The firm has a 50-day simple moving average of $229.10 and a two-hundred day simple moving average of $205.62. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.